Status:
COMPLETED
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Lead Sponsor:
Bayer
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).
Detailed Description
In addition to the key secondary outcome parameters the following parameters will be assessed in an exploratory manner: relative time to progression (TTP), time to symptomatic progression (TTSP), resp...
Eligibility Criteria
Inclusion
- Patients who have a life expectancy of at least 12 weeks
- Patients with advanced HCC (unresectable, and/or metastatic) which has been histologically or cytologically documented
- Patients must have at least one tumor lesion that meets both of the following criteria:
- can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST)
- has not been previously treated with local therapy
- Patients who have received local therapy except chemoembolization, such as surgery, radiation therapy, hepatic arterial embolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation are eligible, provided that they either have a target lesion which has not been subjected to local therapy and/or the target lesion(s) within the field of the local therapy has shown an increase of 25% in the size. Local therapy must be completed at least 4 weeks prior to the baseline scan
- Patients who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Exclusion
- Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Ta, Tis \& T1). Any cancer curatively treated \> 3 years prior to entry is permitted
- History of cardiac disease
- Serious myocardial dysfunction
- Active, clinically serious infections
- Known history of Human Immunodeficiency Virus (HIV) infection
- Known Central Nervous System (CNS) tumors including metastatic brain disease
- Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT00108953
Start Date
April 1 2005
End Date
April 1 2008
Last Update
October 31 2014
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35294
2
Beverly Hills, California, United States, 90211-1850
3
Orange, California, United States, 92668-3298
4
Palo Alto, California, United States, 94304-1207